HIV Mutation Detail Information

> I64M Search Result

Mutation Information

Mutation Site	I64M
Mutation Type	Amino acid level
Gene/Protein/Region Type	PR
Relevant Drug	darunavir;cobicistat;emtricitabine (FTC);tenofovir alafenamide (TAF)
Country	USA

Literature Information

PubMed PMID	31516033
Disease	HIV infection/AIDS
Published Year	2020
Journal	AIDS research and human retroviruses
Title	Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Author	Lathouwers E,Wong EY,Brown K,Baugh B,Ghys A,Jezorwski J,Mohsine EG,Van Landuyt E,Opsomer M,De Meyer S,AMBER and EMERALD Study Groups.
Evidence	One of the three participants in the D/C/F/TAF arm had virus with an emerging secondary PI RAM I64I/L/M. As expected, these secondary PI RAMs had no effect on PI susceptibility.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation